Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies
Open Access Publication
Rights and Permissions
Ghobadi A, Landmann JH, Carter A, Cooper ML, Selli ME, Chang J, Baker M, Miller CA, Ferraro F, Chen DY, Smith AM, LaValle TA, Duncavage EJ, Chou J, Tam V, Benoun JM, Nater J, Scholler N, Milletti F, Vezan R, Bot A, Rossi JM, Singh N. Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies. Blood Adv. 2022 Oct 25;6(20):5634-5640. doi: 10.1182/bloodadvances.2022007705. © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Ghobadi, Armin; Landmann, Jack H; Carter, Alun; Cooper, Matthew L; Selli, Mehmet Emrah; Chang, Jufang; Miller, Christopher A; Ferraro, Francesca; Chen, David Y; Smith, Amanda M; LaValle, Taylor A; Duncavage, Eric J; Singh, Nathan; and et al., "Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies." Blood Advances. 6, 20. 5634 - 5640. (2022).
ICTS (Institute of Clinical and Translational Sciences)
Supplemental material is available for this article at publisher site.